araag2/HINT huggingface dataset:
Clinical trial NCT00416507 (phase 3, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: fluorouracil, gemcitabine hydrochloride, liposomal cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas

          -  No neuroendocrine or other histologies

          -  No extra-abdominal metastases

          -  No hepatic or peritoneal metastases by celioscopy

               -  Peritoneal carcinomatous (cytology positive by peritoneal lavage) may be allowed

          -  Nonresectable disease meeting ≥ 1 of the following criteria:

               -  Arterial invasion

               -  Mesenteric-portal vein invasion > 15 mm and or less than hemicircumference

               -  Satellite adenopathies encompassed in the radiation field

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Bilirubin < 1.75 mg/dL

          -  Creatinine < 1.5 mg/dL

          -  WBC > 1,500/mm³

          -  Platelet count > 100,000/mm³

          -  No major organ disorder, including cardiac or coronary insufficiency

          -  Prothrombin time > 80%

          -  No psychiatric or social condition that would preclude study therapy

          -  No other malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix

          -  No contraindications to radiotherapy or chemotherapy

          -  No intractable pancreatic pain not relieved by morphine and/or analgesic radiotherapy

        PRIOR CONCURRENT THERAPY:

          -  No prior adjuvant or palliative chemotherapy or radiotherapy

          -  Prior surgical diversion of the biliary and/or digestive tract allowed
Clinical trial NCT00296361 (phase 3, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: tacrolimus
SMILES: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients between 18 and 60 years of age and having end stage kidney disease who will
             undergo primary renal transplantation or retransplantation are eligible for the study.
             Patients receiving a kidney transplant, from a cadaveric or living donor (not HLA
             identical) with compatible AB0 blood type can be included.

        Exclusion Criteria:

          -  Patient has a high immunological risk

          -  Cold ischemia time greater than 30 hours

          -  Patient has significant liver disease

          -  Patient has severe hypercholesterolaemia

          -  Patient is allergic or intolerant to study medication

          -  Patient requires ongoing dosing with corticosteroids.

          -  Patient or donor is known to be HIV positive

          -  Patient with malignancy or history of malignancy
Clinical trial NCT00540449 (phase 3, status: completed)
Conditions: hiv infections, hiv-1, human immunodeficiency virus type 1
ICD codes: Z21, B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4, D84.9, D81.9, D83.9, D84.821, B20, D82.2, D84.822
Drugs: tmc278, efavirenz
SMILES: CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with documented HIV-1 infection

          -  Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to
             screening

          -  Patient's HIV-1 plasma viral load at screening is > 5,000 HIV-1 RNA copies/mL (assayed
             by RNA PCR standard specimen procedure)

          -  Patient's virus is sensitive to TDF and FTC

          -  Patient agrees not to start ART (antiretroviral treatment) before the baseline visit

        Exclusion Criteria:

          -  Previous use of ANY ARV drug for ANY length of time

          -  Any documented evidence of NNRTI resistance associated mutations in patient's HIV

          -  Category C AIDS defining illness, except: stable Kaposi Sarcoma, wasting syndrome if
             not progressive

          -  Pneumocystis carinii pneumonia (PCP) that is considered not cured

          -  Active TB

          -  Allergy or hypersensitivity to study or background ARTs

          -  Specific grade 3 or 4 toxicity

          -  Kidney impairment: calculated creatinine clearance <50 ml/min
Clinical trial NCT00443053 (phase 3, status: completed)
Conditions: thrombosis, venous
ICD codes: K64.5, I67.6, O87.3, O22.50, O22.51, O22.52, O22.53
Drugs: fondaparinux 2.5mg or placebo
SMILES: CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
Eligibility criteria:

        Inclusion criteria:

          -  Acute symptomatic superficial thrombophlebitis of the lower limbs at least 5 cm long
             diagnosed by compression ultrasound.

        Exclusion criteria:

          -  Superficial thrombophlebitis that is within 3 cm from the sapheno-femoral junction,

          -  deep vein thrombosis on ultrasound exam, deep vein thrombosis or pulmonary embolism
             within last 6 months, treatment for cancer during last 6 months,

          -  anticoagulant medication for more than 48 hours prior to inclusion,

          -  need for oral non-steroidal anti-inflammatory drugs during the study, significant
             bleeding event during past month,

          -  major surgery within last 3 months, low platelet count (below 100×109/L),

          -  kidney disease (Calculated creatinine clearance < 30 mL/min), woman of child-bearing
             potential not using reliable contraceptive method
Clinical trial NCT00257205 (phase 3, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: dacarbazine, cp-675,206, temozolomide
SMILES: N1C=CN=C1, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Surgically incurable melanoma, either Stage IV or IIIC with N3 status for regional
             lymph nodes and in-transit or satellite lesions.

          -  Serum lactic acid dehydrogenase (LDH) <= 2 x ULN

          -  ECOG performance status of 0 or 1

        Exclusion Criteria:

          -  Received any systemic therapy for metastatic melanoma except post-surgical adjuvant
             treatment with cytokines (eg, alpha-interferon or GM-CSF) or with vaccines after
             complete resection of melanoma.

          -  History of brain metastases
Clinical trial NCT00608374 (phase 3, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: chlorambucil, fludarabine phosphate
SMILES: OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of Waldenström macroglobulinemia, splenic lymphoma with villous lymphocytes
             (SLVL), or non-IgM lymphoplasmacytic lymphoma based on morphological and
             immunophenotypic criteria

               -  Bone marrow should be assessed by two-color flow cytometry for the expression of
                  the following antigens:

                    -  Surface Ig

                    -  CD19

                    -  CD20

                    -  CD5

                    -  CD10

                    -  CD23

          -  Previously untreated disease requiring therapeutic intervention (as judged by the
             primary physician), as indicated by ≥ 1 of the following:

               -  Hemoglobin < 10 g/dL

               -  ANC < 1.5 x 10^9/L

               -  Platelet count < 150 x 10^9/L

               -  Clinical evidence of hyperviscosity in terms of neurological or ocular
                  disturbance

          -  Patients with disease detected by clonal cells alone are not eligible

        PATIENT CHARACTERISTICS:

          -  Performance status 0-2

          -  Life expectancy > 6 months

          -  Serum creatinine < 200 mmol/L

          -  AST and ALT < 2 times upper limit of normal

          -  Negative direct Coomb's test

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 6 months after
             completion of study therapy

          -  No severe or life-threatening cardiac, pulmonary, neurological, psychiatric, or
             metabolic disease

          -  No other concurrent malignancy

          -  No AIDS or AIDS-related complex

          -  No evidence of active hepatitis C infection

        PRIOR CONCURRENT THERAPY:

          -  Prior plasmapheresis for control of clinically significant hyperviscosity allowed

          -  Prior splenectomy for SLVL allowed
Clinical trial NCT00056225 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: folate, vitamin b6, vitamin b12
SMILES: NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1, CC1=C(O)C(CO)=C(CO)C=N1, [C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  National Institute of Neurological Disorders and Stroke (NINDS)/Alzheimer's Disease
             and Related Disorders Association (ADRDA) criteria for probable Alzheimer's disease.

          -  Mini-Mental Status Examination (MMSE) score between 14 and 26, inclusive

          -  Stable medical condition for 3 months

          -  Stable medications for 4 weeks prior to the screening visit

          -  Physically acceptable for this study as confirmed by medical history, physical exam,
             neurologic exam and clinical laboratory tests

          -  Supervision available for administration of study medications

          -  Study partner to accompany subject to all scheduled visits

          -  Fluent in English or Spanish

          -  Modified Hachinski equal to or less than 4 CT or magnetic resonance imaging (MRI)
             since onset of memory impairment demonstrating absence of clinically significant focal
             lesion

          -  Able to complete baseline assessments

          -  6 years of education or work history sufficient to exclude mental retardation

          -  Able to ingest oral medication

        Exclusion Criteria:

          -  B12 or folate deficiency

          -  Renal insufficiency (serum creatinine >=2.0)

          -  Active neoplastic disease (skin tumors other than melanoma are not exclusionary;
             patients with stable prostate cancer may be included at the discretion of the project
             director)

          -  Use of another investigational agent within 2 months

          -  History of clinically significant stroke

          -  Current evidence or history in the past 2 years of epilepsy, focal brain lesion, head
             injury with loss of consciousness and/or immediate confusion after the injury, or
             DSM-IV criteria for any major psychiatric disorder including psychosis, major
             depression, bipolar disorder, alcohol or substance abuse

          -  Blindness, deafness, language difficulties or any other disability which may prevent
             the subject from participating or cooperating in the protocol
Clinical trial NCT00102466 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin, gliclazide, metformin
SMILES: CN(C)C(=N)NC(N)=N, CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  On a stable dose of metformin as defined by the protocol

          -  Blood glucose criteria must be met

          -  Body mass index (BMI) in the range 22-45

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Type 1 diabetes

          -  Evidence of significant diabetic complications

          -  Evidence of serious cardiovascular complications

          -  Laboratory value abnormalities as defined by the protocol

          -  Other protocol-defined exclusion criteria may apply
Clinical trial NCT00398866 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: synvisc (hylan g-f20; hyaluronan injection), bupivicaine (local anesthesia injection), kenalog (triamcinolone; corticosteroid injection)
SMILES: CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O, CNC[C@H](O)C1=CC(O)=C(O)C=C1, [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Presence of osteophytes or sclerosis at the carpometacarpal (CMC) joint

          -  Complaint of unacceptable pain despite modification of activity and a therapeutic dose
             of nonsteroidal anti-inflammatory drugs (NSAIDS), if tolerated

          -  If bilateral disease, only the most severely involved hand (as defined by the visual
             analog scale [VAS] for pain) will be entered in the study

          -  Able to follow instructions and complete questionnaires

          -  Failed conservative therapy with NSAIDS or COX-2 inhibitors

          -  Unable to tolerate COX-2 inhibitors

        Exclusion Criteria:

          -  Previous traumatic dislocation, ligament tear, or fracture of the thumb in the
             affected hand

          -  Previous hand surgery on the affected hand

          -  Known hand comorbidities (e.g., active carpal tunnel syndrome, de Quervains
             tenosynovitis, etc.)

          -  Systemic rheumatic disease

          -  Bleeding diatheses or anti-coagulation

          -  Allergies to steroids, chicken products, bupivicaine, or adhesive (e.g., double-sided
             tape)

          -  Current use of oral or intravenous steroids

          -  Active systemic malignancies

          -  Hyaluronan injection in the target CMC joint in the last 6 months

          -  Steroid or hyaluronan injection in any other joint in the last 6 months

          -  Insulin dependent diabetes mellitus (IDDM)

          -  Active infection

          -  Pain in the index joint that is more than 40 out of 100 on a VAS Pain scale

          -  End Stage CMC osteoarthritis, equivalent to bone on bone, Kellgren and Lawrence Stage
             IV

          -  Grade 3 or 4 Eaton and Litter (E+L) Classification

          -  E+L 3: Advanced joint distraction, subchondral cysts, and sclerosis

          -  E+L 4: Involvement of several joint surfaces
Clinical trial NCT00078260 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of locally advanced or metastatic (Stage III or IV at entry) non-small cell
             lung cancer (NSCLC) that is not amenable to curative therapy.

          -  Patients must have been previously treated with one platinum-containing chemotherapy
             regimen for locally advanced or metastatic disease. Patients are also eligible if they
             have received one platinum-based chemotherapy regimen as neoadjuvant or adjuvant
             chemotherapy, but must have received an additional chemotherapy regimen upon
             recurrence.

          -  No more than two prior systemic anti-cancer therapies will be allowed.

          -  Prior radiation therapy is allowed to less than 25% of the bone marrow. Prior
             radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at
             least 2 weeks before study enrollment, and the patient must have recovered from the
             acute toxic effects of the treatment prior to study enrollment.

        Exclusion Criteria:

          -  Pregnancy.

          -  Breast-feeding.

          -  Second primary malignancy that is clinically detectable at the time of consideration
             for study enrollment.

          -  Inability to interrupt aspirin, or other nonsteroidal anti-inflammatory agents for a
             5-day period.

          -  Inability or unwillingness to take folic acid or vitamin B12 supplementation.
Clinical trial NCT02081183 (phase 3, status: terminated)
Conditions: lupus nephritis
ICD codes: B26.83, A51.44, N11.8, N11.9, N12
Drugs: mycophenolate mofetil (mmf), cyclophosphamide, maintenance phase, cyclophosphamide, induction phase, prednisone
SMILES: COC(=O)\C=C\C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients >=18 years of age;

          -  diagnosis of systemic lupus erythematosus and lupus nephritis (class III, IV or V).

        Exclusion Criteria:

          -  patients who have received cytotoxic drugs in previous 8 weeks;

          -  systemic infections;

          -  hepatitis B or C, or HIV.
Clinical trial NCT01512446 (phase 3, status: terminated)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: alendronate, placebo
SMILES: COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    low recruitment rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women or men > 60 years

          -  DXA T-Score at lumbar spine, total hip or femur neck <-2,0 before the start of the
             bisphosphonate therapy or at baseline or at least one low trauma vertebral fracture
             grade 2-3 or multiple low trauma vertebral fractures independent of bone mineral
             densitiy

          -  Pretreatment with bisphosphonates for at least four years

          -  Risk for hip and vertebral fractures min. 30% according to DVO-guideline for
             osteoporosis 2009

          -  Signed informed consent

        Exclusion Criteria:

          -  Other pharmacological treatment of osteoporosis during the last 48 months

          -  Other bone diseases

          -  Malabsorption syndromes

          -  Renal insufficiency with a calculated creatinine clearance < 35 ml/min

          -  Diseases of the esophagus, delayed esophageal clearance

          -  UUnability to realise the intake instructions

          -  Hypocalcemia
Clinical trial NCT00553787 (phase 3, status: completed)
Conditions: obesity, type 2 diabetes
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vi-0521, vi-0521, vi-0521
SMILES: CC(C)(N)CC1=CC=CC=C1, CC(C)(N)CC1=CC=CC=C1, CC(C)(N)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Informed Consent

          -  BMI ≥ 27 (no lower BMI limit for Type 2 diabetics)

          -  70 years of age or less

          -  Have 2 or more of the following obesity-related co-morbid conditions:

               -  Systolic blood pressure 140-160 mmHg (130-160 if diabetic);

               -  Diastolic blood pressure 90-100 mmHg (85-100 if diabetic);

               -  Requirement for 2 or more medications to achieve control (<140/90 mmHg)

          -  Triglyceride level between 200-400 mg/dL or requirement for 2 or more medications to
             achieve control (<200 mg/dL)

          -  At lease one of the following metabolic criteria:

               -  Fasting blood glucose level > 100 mg/dL

               -  Glucose level > 140 mg/dL

               -  Diagnosis of type 2 diabetes

          -  Waist circumference ≥ 102 cm for men or ≥88 cm for women

        Exclusion Criteria:

          -  Stroke/MI/unstable cardiovascular disease within 6 months

          -  Clinically significant renal, hepatic or psychiatric disease

          -  Unstable thyroid disease or replacement therapy

          -  Nephrolithiasis

          -  Obesity of known genetic or endocrine origin

          -  Participation in a formal weight loss program or lifestyle intervention

          -  Glaucoma or intraocular pressure

          -  Pregnancy or breastfeeding

          -  Drug or Alcohol abuse

          -  Smoking cessation within previous 3 months or plans to quit smoking during study

          -  Eating disorders

          -  Cholelithiasis within past 6 months

          -  Excluded medications

          -  Type 1 diabetes or use of any antidiabetic medication other than metformin

          -  Previous bariatric surgery

          -  Bipolar disorder or psychosis

          -  Steroid hormone therapy

          -  Systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg

          -  Creatinine clearance < 60 mL/minute
Clinical trial NCT00111007 (phase 3, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: sorafenib (nexavar, bay43-9006), carboplatin/paclitaxel, placebo
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who have a life expectancy of at least 12 weeks

          -  Subjects with histologically or cytologically confirmed unresectable (Stage III) or
             metastatic (Stage IV) melanoma

          -  Subjects must have progressed after receiving at least one cycle of DTIC or TMZ
             containing regimen

          -  Subjects who have an ECOG PS of 0 or 1

          -  Measurable disease defined as at least one lesion that can be accurately and serially
             measured per the modified RECIST criteria

        Exclusion Criteria:

          -  Primary ocular or mucosal melanoma

          -  Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in this study except cervical carcinoma in situ, treated basal
             cell carcinoma, superficial bladder tumors (Ta [Noninvasive papillary carcinoma], Tis
             [Carcinoma in situ: "flat tumor"]& T1 [Tumor invades subepithelial connective tissue])
             or any cancer curatively treated < 5 years prior to study entry

          -  History of cardiac disease

          -  Known history of human immunodeficiency virus (HIV) infection